4-氟-3-(哌啶-4-基)苄基氨基甲酸叔丁酯 | 823195-19-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-氟-3-(哌啶-4-基)苄基氨基甲酸叔丁酯
• 英文名称: tert-butyl 4-fluoro-3-(piperidin-4-yl)benzylcarbamate
• 英文别名: (4-fluoro-3-piperidin-4-yl-benzyl)carbamic acid tert-butyl ester；4-[5-(tert-Butoxycarbonylaminomethyl)-2-fluorophenyl]piperidine；tert-butyl N-[(4-fluoro-3-piperidin-4-ylphenyl)methyl]carbamate
• CAS: 823195-19-3
• 化学式: C₁₇H₂₅FN₂O₂
• 分子量: 308.396
• InChiKey: MFRZZHOXGKQYOU-UHFFFAOYSA-N

物化性质

• 沸点：
  427.4±45.0 °C(Predicted)
• 密度：
  1.093±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-氟-3-(哌啶-4-基)苄基氨基甲酸叔丁酯 在 盐酸 、 O-[(ethoxycarbonyl)cyanomethyleneamino]-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N-乙基二丙胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-[4-(5-Aminomethyl-2-fluoro-phenyl)-piperidine-1-carbonyl]-5-(3-thiophen-2-yl-[1,2,4]oxadiazol-5-yl)-benzoic acid
  参考文献：
  名称：

  Design of bivalent ligands using hydrogen bond linkers: synthesis and evaluation of inhibitors for human β-tryptase

  摘要：

  We exploit the concept of using hydrogen bonds to link multiple ligands for maintaining simultaneous interactions with polyvalent binding sites. This approach is demonstrated by the syntheses and evaluation of pseudo-bivalent ligands as potent inhibitors of human (beta-tryptase. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.09.065
• 作为产物：
  描述：

  (4-fluoro-3-piperidin-4-yl-benzyl)carbamic acid tert-butyl ester acetate salt 在 盐酸 、 sodium hydroxide 作用下， 以 水 为溶剂， 以98%的产率得到4-氟-3-(哌啶-4-基)苄基氨基甲酸叔丁酯
  参考文献：
  名称：

  [EN] [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE HYDROCHLORIDE AS AN INHIBITOR OF MAST CELL TRYPTASE
  [FR] [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE HYDROCHLORURE TENANT LIEU D'INHIBITEUR DE LA MASTOCYTE TRYPTASE

  摘要：

  本发明涉及到式I的化合物，或者该化合物的前药、药学上可接受的盐或溶剂。此外，本发明涉及一种药物组合物，包括式I的化合物的药学有效量和药学上可接受的载体。此外，本发明涉及将式I的化合物用作色氨酸蛋白酶抑制剂的用途，包括将该化合物引入含有色氨酸蛋白酶的组合物中。此外，本发明还涉及将式I的化合物用于治疗患有或患有需要改善色氨酸蛋白酶抑制剂的生理状况的患者的用途，包括向患者施用权利要求1中的化合物的治疗有效量。本发明还涉及制备式I的化合物。

  公开号：

  WO2005097780A1

文献信息

• MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME
  申请人：Barany Francis

  公开号：US20140194383A1

  公开（公告）日：2014-07-10

  Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.

  本发明描述了在水中介质中与一个、两个、三个或更多其他单体接触时能够形成具有生物学用途的多聚体的单体。在一方面，这样的单体可能能够在水介质中（例如，体内）与另一个单体结合形成多聚体（例如，二聚体）。考虑的单体可能包括一个配体部分、一个连接元素和一个连接器元素，连接器元素连接配体部分和连接元素。在水介质中，这样的考虑单体可能通过每个连接元素相互连接，因此可能能够实质上同时调节一个或多个生物分子，例如，调节蛋白质上的两个或多个结合域，或者调节不同蛋白质上的结合域。
• [EN] SYNTHESIS OF (4-FLUORO-3-PIPERIDIN-4-YL-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER AND INTERMEDIATES THEREOF<br/>[FR] SYNTHÈSE DE L'ESTER TERT-BUTYLIQUE DE L'ACIDE (4-FLUORO-3-PIPÉRIDIN-4-YL-BENZYL)-CARBAMIQUE ET INTERMÉDIAIRES CORRESPONDANTS
  申请人：SANOFI AVENTIS US LLC

  公开号：WO2011037947A1

  公开（公告）日：2011-03-31

  The present invention is an improved method for the preparation of 4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester, compound of formula I. The invention is directed to a method of synthesis for the compound of formula I in three steps, comprising formation of 5-((tert-butoxycarbonyl)aminomethyl)-2-fluorobenzeneboronic acid (compound 11), reaction of compound 11 under Suzuki coupling conditions to yield (4-fluoro-2-pyridin-4-yl-benzyl)-carbamic acid tert-butyl ester and selective hydrogenation of the aforementioned product under hydrogenation conditions yields compound I. The invention is also directed to the intermediates 5-((tert-Butoxycarbonyl)amino-methyl)-2-fluorobenzeneboronic acid (compound 11), and (4-fluoro-2-pyridin-4-yl-benzyl)-carbamic acid tert-butyl ester (compound 13).

  该发明是一种改进的制备4-氟-3-哌啶-4-基苄基)氨基甲酸叔丁酯（化合物I）的方法。该发明涉及一种合成化合物I的三步方法，包括形成5-((叔丁氧羰基)氨甲基)-2-氟苯硼酸（化合物11），将化合物11在铜促进的Suzuki偶联条件下反应，得到(4-氟-2-吡啶-4-基苄基)氨基甲酸叔丁酯，并在氢化条件下选择性氢化上述产物得到化合物I。该发明还涉及中间体5-((叔丁氧羰基)氨基甲基)-2-氟苯硼酸（化合物11）和(4-氟-2-吡啶-4-基苄基)氨基甲酸叔丁酯（化合物13）。
• COFLUORONS AND METHODS OF MAKING AND USING THEM
  申请人：Barany Francis

  公开号：US20140161729A1

  公开（公告）日：2014-06-12

  The present invention is directed to method of using a collection of monomers capable of forming multimers as a fluorescence reporter in different applications such as ligand detection/screening, disease diagnosis, drug discovery or screening, fluorescent labeling and imaging, or other fluorescent methodologies. Each monomer in the collection includes one or more ligand elements useful for binding to a target molecule with a dissociation constant of less than 300 μM and a linker element connected to the ligand elements directly or indirectly through a connector. Association of linker elements of different combinations of monomers, with their ligand elements bound to the target molecule to form a multimer, will generate a unique fluorescent signature different from that produced by those monomers either alone or in association with each other in the absence of the target molecule, when subjected to electromagnetic excitement.

  本发明涉及使用一组能够形成多聚体的单体作为荧光报告物在不同应用中的方法，例如配体检测/筛选、疾病诊断、药物发现或筛选、荧光标记和成像，或其他荧光方法学。该组合中的每个单体均包括一个或多个配体元素，用于与解离常数小于300μM的靶分子结合，并且连接到配体元素的连接器通过直接或间接连接到配体元素。不同单体组合的连接器元素与其配体元素结合到靶分子形成多聚体，将产生一种独特的荧光特征，与那些单体单独或在没有靶分子的情况下相互结合时产生的荧光特征不同，当受到电磁激发时。
• [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase
  申请人：Gao Zhongli

  公开号：US20070142435A1

  公开（公告）日：2007-06-21

  The present invention extends to the compound of formula I: or a prodrug, pharmaceutically acceptable salt, or solvate of said compound. Furthermore, the present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula I, and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed to the use of a compound of formula I as an inhibitor of tryptase, comprising introducing the compound into a composition comprising tryptase. In addition, the present invention is directed to the use of a compound of formula I for treating a patient suffering from, or subject to, a physiological condition in need of amelioration of an inhibitor of tryptase comprising administering to the patient a therapeutically effective amount of the compound of claim 1 The present invention is directed also to the preparation of a compound of formula I.

  本发明涉及化合物I的化合物：或者其前药、药学上可接受的盐或溶剂。此外，本发明涉及一种药物组合物，包括药学有效量的化合物I和药学上可接受的载体。此外，本发明涉及使用化合物I作为组成三胺酸酶抑制剂的用途，包括将化合物引入包含三胺酸酶的组成物中。此外，本发明还涉及使用化合物I治疗患有或受到需要改善三胺酸酶抑制剂的生理状况的患者，包括向患者施用化合物的治疗有效量。本发明还涉及制备化合物I的方法。
• Process for the preparation of tryptase inhibitors
  申请人：Graf Claus-Dieter

  公开号：US20070197597A1

  公开（公告）日：2007-08-23

  This invention is directed to processes for the preparation of a compound of the formula I or salt thereof, that is useful as a tryptase inhibitor, to intermediates useful in the preparation of such a compound, to processes for the preparation of such intermediates, and to the use of such intermediates for the preparation of such a compound.

  本发明涉及制备式I化合物或其盐的工艺，该化合物可用作tryptase抑制剂，还涉及制备这种化合物的有用中间体，制备这种中间体的工艺，以及使用这种中间体制备这种化合物的方法。